GLOW vs KLOW

GLOW vs KLOW, component by component

Both blends are built on the same base: 50mg of GHK-Cu with 10mg each of BPC-157 and TB-500. KLOW adds a fourth, KPV, at 10mg. That is the entire difference in composition, and it accounts for the 10mg difference in total mass.

Both arrive as a blue cake of lyophilized powder. The colour comes from the copper in the GHK-Cu copper peptide, which is by a wide margin the largest component of either blend, and it is why neither of these looks like the white cake of a single-compound vial.

The arithmetic is worth stating rather than leaving implied. An 80mg vial against a 70mg vial is a 14.3% rise in peptide mass. GHK-Cu is 71.4% of a GLOW vial by mass and 62.5% of a KLOW vial, so the extra KPV does not change how much GHK-Cu is present, only what proportion of the vial it represents. Three of the four named components are common to both, which is where the often-repeated claim that the two blends share 75% of their composition comes from: that figure counts components, not mass. By mass the shared base is 87.5% of a KLOW vial and all of a GLOW one.

Set out that way, the comparison is of four named molecules in which three are held constant. Everything further down this page follows from that. The molar picture, the certificate, the price per milligram and the fixed ratio all behave the same way in both vials, because most of the list is the same list.

GLOW vs KLOW: the molar picture the mass ratio hides

Every listing in this category quotes a mass ratio, 50:10:10 for GLOW and 50:10:10:10 for KLOW, and every listing stops there. Mass is the wrong unit for a mixture of molecules with very different weights, because what a bench assay meets is a number of molecules, not a number of milligrams. Converting is one division: micromoles equal milligrams divided by molecular weight in grams per mole, times a thousand.

Done for GLOW, the result is not close to 50:10:10. GHK-Cu, at 403.94 g/mol, contributes 123.8 micromoles. BPC-157, at 1419.53, contributes 7.04. TB-500, at 889.0, contributes 11.25. GHK-Cu is therefore 87.1% of the molecules in a GLOW vial and outnumbers BPC-157 by about 17.6 to one. The label ratio of five to one understates the real dominance by a factor of three and a half.

KPV changes the picture more than its mass suggests. At 342.4 g/mol it is the lightest of the four, so 10mg of it is 29.2 micromoles, more than four times the molar contribution of the 10mg of BPC-157 sitting beside it. On a mass basis KPV and BPC-157 are equal at 12.5% of a KLOW vial each. On a molar basis KPV is 17.0% and BPC-157 is 4.1%. In molar terms, then, GLOW vs KLOW is a larger change than the 10mg printed on the label suggests.

None of this is a claim about anything. It is division applied to published molecular weights, and it is the figure a protocol working in molar concentrations needs before it can use either vial. It is also the reason a blend's fixed ratio is a harder constraint than it looks: the mass ratio a vendor chose to print is not the ratio the material is actually in.

GLOW vs KLOW: two vendor names, not two formulations

There is no standards body for research blends. GLOW and KLOW are trade names that vendors apply to whatever they have decided to put in a vial, and the listings currently ranking for this query do not agree with one another about what either name means.

The table below is composition as published, taken from live listings surveyed in September 2026. Four of the six carry a 50:10:10 base of GHK-Cu, BPC-157 and TB-500, one of those four with KPV added as a fourth component. One states 30:20:20, also totalling 70mg: the same mass, a completely different formulation. One sells a 30mg product under the same name and itemises nothing at all. Every one of them is sold as GLOW.

The vendors are described by type rather than named, and deliberately so. A composition read on one date is a statement about a page that can be edited the following morning, so a survey pinned to a company name goes stale without anyone being told. What is durable is the pattern rather than the roster: one four-letter name sitting above three different answers to the question of what is in the vial, and a fourth listing that declines to answer it. Naming the vendors would add nothing to that pattern and would date this page the first time one of them edited a product description.

The conclusion is uncomfortable but simple. The name on a blend vial carries no information about composition, and the mass on the label carries very little: 70mg of peptide can be three quite different things. The only document that says what is in a given vial is a certificate that reports each component separately and matches the lot number printed on the glass.

There is a practical test that costs nothing. Before comparing two blends on price, check whether each listing itemises its components in milligrams. A listing that names a total and not a breakdown has not told anyone what is being bought, and a listing that names a breakdown can at least be checked against the certificate for the lot in hand.

It is also why GLOW vs KLOW is only a meaningful comparison between two vials whose composition is published in milligrams. Our own profiles of the GLOW peptide and the KLOW peptide state that breakdown for each, and the certificate for the lot does the rest.

Why a blend cannot have one purity figure

A purity percentage answers the question 'of the material present, how much was the target'. In a blend there are three or four targets, so the question has to be asked separately for each one. A single number across a mixture is not a measurement of anything in particular.

This is where blends in this category most often go wrong. A listing that states one purity figure for a four-component product has either assayed one component and applied its number to the whole vial, or has quoted a figure with no defined meaning. Neither tells anyone whether the KPV in a KLOW vial is what it claims to be.

Our certificates for both blends report each component separately, identity and purity one line at a time, and the overall figures shown on the product pages, 99.68% for GLOW and 99.76% for KLOW, are summaries of those per-component results rather than substitutes for them. The full report is published against the lot number on the vial.

The methods are worth naming, because almost nothing written on this subject does. Purity is measured by reversed-phase HPLC, which separates the contents of the vial in time and integrates the area under each peak. Identity is confirmed by LC-MS, which measures the mass of what came off the column and compares it with the calculated mass of the intended molecule. The first method says how much; the second says what. A blend needs both, once per component, which is what peptide purity testing sets out at length.

That is also why a mass-spectrometry result is not transferable between blends. An LC-MS run confirms the molecules it was set up to look for. A GLOW certificate confirming GHK-Cu, BPC-157 and TB-500 says nothing whatever about KPV, because KPV was not among the masses sought. A KLOW vial therefore needs four confirmations, not three plus an assumption.

On documentation, then, GLOW vs KLOW is a difference of one line rather than of one molecule: three identity results and three purity results on one side, four of each on the other.

What our own certificates report, line by line

Naming a standard is easy; publishing the results is the part that can be checked. Every lot released under both names is filed in the certificate library, including lots long out of stock, and the table below is what those documents actually say. All of them were reported by Freedom Diagnostics, a third-party laboratory, with identity confirmed by LC-MS.

Three things in that table are worth pointing at, and none of them would be visible under a single blended figure. First, measured content is not label content. A GLOW lot labelled 50mg of GHK-Cu measured 59.92mg; a KLOW lot labelled 10mg of KPV measured 8.80mg. Released lots run at or slightly above label on the large component and close to it on the small ones, and only a per-component assay can show that at all.

Second, the certificates are not consistent about what they call the thymosin component. Some lots report it as TB-500 and some as Thymosin Beta-4, which is the parent 43-residue protein rather than the seven-residue acetylated fragment. That inconsistency belongs to the analysing laboratory's naming rather than to the material, and it is published as written rather than tidied up, because a certificate edited for presentation is no longer a certificate.

Third, the overall figures move from lot to lot: 99.544% to 99.905% across four published GLOW lots, and 99.613% to 99.76% across three KLOW lots. A vendor quoting one fixed purity number for a blend, forever, is quoting a marketing figure rather than a measurement. The lot number on the glass is what resolves to a specific document, and it can be read before anything is ordered rather than after.

Read across both names, the published lots carry the same structure: one line per component, the analysing laboratory named, a method named and a date. The number of lines is the only thing that changes between the two.

Why blends exist at all

A blend is a convenience and a constraint at the same time. The convenience is obvious: one vial, one reconstitution, one set of handling decisions instead of three or four. For a model system that calls for all of the components together, that is a real saving in time and in glassware.

The constraint is that the ratio is fixed. GLOW is 50:10:10 and KLOW is 50:10:10:10, and nothing about either can be varied without buying the components separately. Where a design needs one component at a different proportion, single vials are the only option.

There is a documentation consequence too. A blend can only be as well characterised as its weakest component, and the report has to cover each of them. That is why the per-component certificate matters more here than it does on a single-compound vial.

The constraint compounds once a vial is in solution. A single-compound vial can be diluted to whatever concentration a design calls for, and every other variable stays where it was. Diluting a blend moves all three or four concentrations at once, in the fixed proportion the vendor chose. There is no way to halve the GHK-Cu in a GLOW vial without halving the BPC-157 and the TB-500 with it.

On that constraint GLOW vs KLOW behaves identically. Both fix their ratio, both move every concentration together on dilution, and both leave a design that needs one component on its own with no option but a single vial.

GLOW vs KLOW: what a millilitre of each contains

Concentration is arithmetic, and it is the one figure a blend makes slightly awkward, because a vial holds several concentrations at once rather than one. The sums below divide the label mass of each component by the volume of solvent added. They are not a protocol and they carry no recommendation: this catalogue is supplied for in-vitro laboratory work, and nothing here describes administration of any kind.

Taking 2mL as a round number, a GLOW vial gives 25 mg/mL of GHK-Cu and 5 mg/mL each of BPC-157 and TB-500, for 35 mg/mL of peptide in total. A KLOW vial gives the same three plus 5 mg/mL of KPV, for 40 mg/mL. Because the components differ so much in molecular weight, the molar concentrations are much further apart than the mass concentrations: 61.9 mM of GHK-Cu against 3.52 mM of BPC-157 in the same millilitre.

Both blends dissolve in the same solvent, and the case for bacteriostatic water for peptides is the same here as it is for a single-compound vial. The water itself is the same product; the difference is only that the answer applies to four molecules at once.

In solution, then, GLOW vs KLOW differs by one line of the table below and by nothing else in it.

Copper chemistry and the stability of a blend

GHK-Cu is not a peptide with copper added. It is a coordination complex in which a copper(II) ion is held by the glycyl-histidyl-lysine backbone, and that copper is the reason the cake is blue and the reason the complex behaves differently from the three ordinary peptides beside it. Copper complexes are more sensitive to oxidation and to shifts in pH than plain peptide chains, and they can exchange their metal ion with other ligands present in solution.

For a blend this matters more than it would for a single vial, because stability is set by the least stable component and here that component is 62.5% to 71.4% of the mass. Whatever handling a blend receives is effectively handling designed around GHK-Cu, and the other three inherit it.

Solvent chemistry is part of that. The FDA label for the reference bacteriostatic water product gives a pH of 5.7, mildly acidic, which is the environment a reconstituted blend sits in. That is a property of the solvent rather than a warning about it, and it is one of the few numbers in this subject that can be looked up rather than inferred. A separate note on what is bacteriostatic water sets out the rest of that label.

Nothing in the handling table below distinguishes the two, which is the point. On handling, GLOW vs KLOW is not a choice at all: the base is identical, so how to store peptides is one decision rather than two, and only the number of components that have to be re-verified changes.

GLOW vs KLOW vs the other ways to buy the same molecules

Three other things are routinely compared against these two: the two-peptide BPC-157 and TB-500 pairing, stocked here as the Repair Reference Panel; GHK-Cu on its own; and the individual vials taken together. The comparison is entirely compositional, and it fits in one table.

Read down the first two columns and the difference is KPV. Read across and a second question appears, which is whether a blend is the right container at all. The BPC-157 and TB-500 pairing carries 20mg of peptide against GLOW's 70mg, but 20mg of the two components most listings describe as the expensive ones, and how those two differ from each other, BPC-157 vs TB-500, is its own question. GHK-Cu alone carries the same 50mg found in either blend, in a vial that costs a third of what the blend does.

That is not an argument against the blends. It is the reason the per-milligram question in the next section is the one worth asking, because total mass in a vial is dominated by whichever component is cheapest per milligram, and in both of these, it is.

Widened that far, GLOW vs KLOW stops being the only comparison on the table and becomes two columns of four.

GLOW vs KLOW: the cost per milligram of the component that matters

Comparing blends on price per milligram of total peptide produces a figure that looks precise and means almost nothing. GLOW works out at $1.71 per mg and KLOW at $1.75 per mg, which makes them look near-identical and both look cheap. They look cheap because two-thirds to three-quarters of the mass being divided into is GHK-Cu, the least expensive peptide in this catalogue per milligram.

The useful comparison is against the component the work actually concerns. A 100mg GHK-Cu vial is $0.60 per milligram and the 50mg vial is $0.80. BPC-157 is $6.00 per milligram and TB-500 is $8.50. Those three numbers explain the blend prices completely: the 10mg of BPC-157 and 10mg of TB-500 inside a GLOW vial would cost $144.98 as single vials, or $129.99 bought as the two-vial panel, against $39.99 for the 50mg of GHK-Cu beside them.

Set against that, GLOW at $119.99 is less than the $169.98 the same three quantities cost as a panel plus a GHK-Cu vial, and considerably less than the $184.97 they cost as three separate single vials. The saving is real; it is bought with the fixed ratio and with three certificate lines to read instead of one per vial.

Between the two blends the premium is $20, and it buys 10mg of KPV. There is no single-component KPV vial in this catalogue to price it against, so unlike every other component in either blend, the KPV premium cannot be checked against a standalone figure. Stating that plainly is more useful than an invented comparison.

On price, then, GLOW vs KLOW is a $20 question with one variable in it, and that variable is the only component of the four that cannot be priced on its own.

What neither blend has

Neither blend is a new molecular entity. Neither has an International Nonproprietary Name, a pharmacopoeial monograph or a CAS number of its own, which is why the CAS field on both product pages reads 'Blend, see COA' rather than a number. Both are mixtures of separately known molecules, and that is the whole of their regulatory identity.

Neither has been studied as a formulation. There are no controlled studies of GLOW as GLOW or KLOW as KLOW; the count is zero, and every page on this subject that appears to cite evidence for a blend is in fact citing evidence for one of its components. Four of the eight best-ranked pages for this query say so themselves, which is to their credit.

What does exist is a separate preclinical literature for each of the four, in defined model systems, at concentrations and in preparations that have nothing to do with a blended vial. The table below names what those literatures study and one primary source for each, so a reader can go to the paper rather than to a vendor's summary of it.

The gap between that table and a vial of blend is the important thing on this page. Evidence gathered in a cell-culture model, for one molecule, at one concentration, does not transfer across a change of concentration, a change of preparation, or the addition of three other molecules. Everything in this catalogue is supplied for in-vitro laboratory research only, and nothing on this page describes use in humans or animals.

GLOW vs KLOW is therefore a comparison of composition and of documentation. It cannot be a comparison of evidence, because there is no evidence about either mixture as a mixture.

GLOW vs KLOW: how the two compare in practice

Because the base is identical, anything true of GLOW's handling is true of KLOW's. Both are stored at −20°C for the long term and 2 to 8°C in solution. Both dissolve in bacteriostatic water. Both are blue.

The choice between them is therefore a choice about whether a model system calls for KPV alongside the other three. Where it does not, GLOW is the same three components at a lower total mass and a lower price; where it does, KLOW supplies it in the same vial rather than requiring a separate one.

A related question people ask is what combining the two vials would give. Compositionally the answer is a 150mg mixture: 100mg of GHK-Cu, 20mg each of BPC-157 and TB-500, and 10mg of KPV. That is not either blend at a larger scale. It is a different ratio, with GHK-Cu rising to 66.7% of mass and KPV falling to 6.7%. Whatever proportion a blend was designed around, combining the two does not preserve it.

Put at its shortest, GLOW vs KLOW is settled by one question about KPV and by two certificates, and by nothing else in either vial.

As with everything in this catalogue, both are supplied for in-vitro research use only, and nothing here describes use in humans or animals.